Metoclopramide News and Research

RSS
Salix first quarter total product revenue increases 62% to $171.1M

Salix first quarter total product revenue increases 62% to $171.1M

Greater patient and healthcare provider dialogue needed for morning sickness

Greater patient and healthcare provider dialogue needed for morning sickness

Salix third quarter total product revenue increases 81% to $146.2 million

Salix third quarter total product revenue increases 81% to $146.2 million

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

U.S. Supreme Court ruling on generic drugs

U.S. Supreme Court ruling on generic drugs

Supreme Court ruling would affect around 10,000 Reglan-metoclopramide lawsuits

Supreme Court ruling would affect around 10,000 Reglan-metoclopramide lawsuits

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Lupin grants Salix exclusive worldwide rights to rifaximin

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Masimo's noninvasive SpMet provides measurements comparable to invasive methemoglobin testing

Masimo's noninvasive SpMet provides measurements comparable to invasive methemoglobin testing

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Despite FDA black box warning, prescription of Reglan for premature infants continue

Despite FDA black box warning, prescription of Reglan for premature infants continue

Implementation of quality improvement intervention reduces medication use in premature babies: Study

Implementation of quality improvement intervention reduces medication use in premature babies: Study